Laurus Labs receives EIR from USFDA for Visakhapatnam units
Drug firm Laurus Labs on Thursday said it has received an establishment inspection report from the US health regulator for two of its active pharmaceutical ingredients units at Visakhapatnam in Andhra Pradesh. The establishment inspection report (EIR) from US Food and Drug Administration (USFDA) is for company's active pharmaceutical ingredients units 1 and 3, at Visakhapatnam, for the inspection conducted in June 2019, Laurus Labs said in a filing to BSE. The company has also received approval from the Global Fund (GF) expert review panel for its fixed dose combination, TLE 400, for supply in GF-funded projects, it added. Laurus Labs is one among the three companies to receive the approval for this product in antiretroviral therapy, the company said.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
